Skip to main content

SEngine Precision Medicine's Lab Garners CLIA Certification

NEW YORK (GenomeWeb) – SEngine Precision Medicine said today that its Seattle-based laboratory has received CLIA certification.

The company's primary test offering, called PARIS, combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

SEngine said that its CLIA Laboratory now simultaneously screens up to 120 individual drugs and selected drug combinations.

"We can now offer patients and their doctors a test to help determine the best drug match for a particular cancer based on high-throughput screening and genomic profiling," SEngine Precision Medicine CEO Carla Grandori said in a statement. Grandori added that the company plans to make its assays "widely available."

Last month, SEngine said that it had signed an exclusive licensing agreement with Fred Hutchinson Cancer Research Center giving it rights to market the test to aid in personalized cancer therapy selection.